Canaccord Genuity Keeps a Buy Rating on Aphria Inc

By Jason Carr

Wall Street analyst has provided a review for the Healthcare company today, but retained the same rating on the stock. Analyst Matt Bottomley from Canaccord Genuity reiterated a Buy rating on Aphria Inc (TSXV: APH), with a C$25.50 price target.

According to, Bottomley is ranked #231 out of 4774 analysts.

Aphria Inc has an analyst consensus of Moderate Buy, with a price target consensus of C$25.38.

Aphria Inc’s market cap is currently C$1.86B and has a P/E ratio of 67.1.

Aphria, Inc. engages in the production and supply of medical marijuana. Its products include alien dawg, champlian indica, grower’s blend, champlain-sativa and blueberry. The company was founded by Cole Cacciavillani and John Cervini on June 22, 2011 and is headquartered in Leamington, Canada.

The company’s shares closed on Monday at C$12.24.